Investigating the effect of magnesium supplement in patients with major depressive disorder under selective serotonin reuptake inhibitor treatment
Nazarinasab M, Behrouzian F, Abdi L, Sadegh Moghaddam AA, Sadeghi S
Journal of family medicine and primary care · 7 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (clasificado por nuestro filtro de IA)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
Según la declaración de financiación del texto completo.
Publicación
- Publicado
- 2022-12-01 · J Family Med Prim Care · vol. 11 · número 12 · págs. 7800–7805
- Editorial
- Medknow
- Citado
- 7 citas · más que el 67% de estudios similares · 0.7× el promedio de su campo
- Referencias
- 24 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY-NC-SA
- Áreas de investigación
- Magnesium in Health and Disease · Thallium and Germanium Studies · Cardiac Health and Mental Health
- Palabras clave
- Medicine, Major depressive disorder, Serotonin reuptake inhibitor, Internal medicine, Fluoxetine, Randomized controlled trial, Anxiety, Depression (economics), Mood, Psychiatry, Placebo, Beck Depression Inventory, Mood disorders, Antidepressant, Serotonin
5 autores
- Masoumeh Nazarinasab🇮🇷 · autor de correspondenciaAhvaz Jundishapur University of Medical Sciences
- Forouzan Behrouzian🇮🇷Ahvaz Jundishapur University of Medical Sciences
- Leila Abdi🇮🇷Ahvaz Jundishapur University of Medical Sciences
- Amir Ali Sadegh Moghaddam🇮🇷Ahvaz Jundishapur University of Medical Sciences
- Susan Sadeghi🇮🇷Ahvaz Jundishapur University of Medical Sciences
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Major depression disorder (MDD) is a mental disorder that affects millions of people worldwide. This disease has negative impacts on quality of life and psychological-related functions. This is a multifactorial disorder; both genetic background and environmental factors have their role. Antidepressants are prescribed as the first line of treatment for patients with depressive disorders. Selective serotonin reuptake inhibitor (SSRI) antidepressants are used to treat MDD and anxiety; however, some patients do not respond to them. Regarding that, magnesium plays a major role in mood regulation; therefore, this study aimed to investigate the role of magnesium supplement in patients with MDD and under an SSRI treatment regimen.
Methods
In this randomized, double-blind controlled trial, 60 patients with major depressive disorders based on the DSM-V diagnosis referred to Golestan Hospital in Ahvaz, Iran, were included. The eligible patients were categorized randomly into two thirty-people groups receiving magnesium (intervention) and placebo (control) along with SSRI for 6 weeks. To evaluate the depression status, the Beck II test was applied. Subjects were examined before and after the intervention.
Results
There was no statistically significant difference between the two groups in terms of demographic characteristics (P > 0.05). The mean Beck scores at the beginning of the study and the second week after the intervention were not different between the two groups (P = 0.97, P = 0.56), whereas the mean Beck scores were lower in the intervention group than in the control group in the fourth and sixth weeks after the intervention (P = 0.02 and P = 0.001, respectively).
Conclusion
Administration of Mg supplement for at least 6 weeks might improve depression symptoms. It can also be considered as a potential adjunct treatment option for MDD patients who are under SSRI treatment.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC-SA).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.